Commercial Considerations in the Development of Therapy-Enabling Technologies

Scientific literature and popular media provide a stream of
breakthrough reports with promise for addressing critical medical
needs. Often, these hopes are displaced by the next wave
of reports before being fulfi lled with actual medical treatments.
Many of the factors contributing to high attrition rates can be
addressed at early stages by scientists working in these fields.
This lecture will address commercial issues facing new technologies
with therapy-enabling potential, with case-study examples
drawn from nanotechnology, siRNA, and gene therapy.